P3 is over-expressed in a variety of myeloid leukemias, including 75% of CML patients, [18] and may be involved in the process of leukemia transformation or maintenance of the leukemia phenotype [19] via the proteolytic regulation of the cyclin dependent kinase inhibitor p21waf1[20]. Here, CDKN3 is linked to leukemia.